Allied World Assurance (AWH) Prices 12M Share Offering at $0.75/sh

Aspira Women’s Health Inc. (Nasdaq: AWH) (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced the pricing of the previously announced underwritten public offering of 12,000,000 shares of its common stock and warrants to purchase an aggregate of 12,000,000 shares of its common stock at a combined price to the public of $0.75 per share of common stock and accompanying warrant. Each warrant will have an exercise price of $0.88 per share and will be exercisable during the period commencing on the closing date of the offering and ending five years following such date. All of the securities are being offered by Aspira.

William Blair & Company, L.L.C. is acting as the sole book-running manager for the proposed offering.

The offering is expected to close on August 25, 2022, subject to customary closing conditions.

Gross proceeds from the offering are expected to be $9.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Aspira. Aspira intends to use the net proceeds from the offering for working capital and other general corporate purposes, including product portfolio expansion and commercialization. Aspira may also use a portion of the net proceeds from the offering to invest in complimentary businesses, strategic partnerships, technologies or other intellectual property.

The offering is being made pursuant to a shelf registration statement (File No. 333-252267) previously filed with, and declared effective by, the U.S. Securities and Exchange Commission (the “SEC”). A preliminary prospectus supplement, dated August 22, 2022, and accompanying prospectus, dated January 28, 2021, relating to the offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov. To obtain a copy of the final prospectus supplement for the offering (when available), please contact William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at 1-800-621-0687 or by e-mail at [email protected].

This press release is for informational purposes only and shall not constitute an offer to sell or a solicitation of an offer to buy securities in any state or other jurisdiction in which such offer or sale is not permitted.

You May Also Be Interested In

• Outlook Therapeutics launches public offering of stock and warrants
• Thunder Bridge Capital Partners V prices $261M IPO on Nasdaq
• SEC files civil complaint against Netcapital and certain individuals